Chasing a 'master modulator' in the endocannabinoid system, biotech upstart promises to shake up neuropsychiatric treatments
For two years in the early 2000s, new discoveries and budding enthusiasm around the endogenous cannabinoid system — so named because it’s responsible for the effects …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.